To date, there are no pharmacological activators of LKB1; however, metformin, an FDA-approved drug for T2DM, is a pharmacological activator of AMPK, and thus we asked whether metformin can enhance the antiproliferative activity of EGFR TKI to overcome resistance. The gene discussed is STK11; the disease is type 2 diabetes mellitus.